Literature DB >> 24926049

Genome Sequence of SCB34, a Sequence Type 131 Multidrug-Resistant Escherichia coli Isolate Causing Neonatal Early-Onset Sepsis.

Susana Chavez-Bueno1, Michael W Day2, Inimary T Toby2, Darrin R Akins2, David W Dyer2.   

Abstract

SCB34 is a sequence type 131, highly invasive, multidrug-resistant Escherichia coli isolate that produced neonatal bacteremia. Whole-genome sequencing was performed using a 250-bp library on the Illumina MiSeq platform; 5,910,264 reads were assembled de novo using the A5 assembly pipeline. The total contig length was 5,227,742 bp; the RAST server was used for annotation.
Copyright © 2014 Chavez-Bueno et al.

Entities:  

Year:  2014        PMID: 24926049      PMCID: PMC4056292          DOI: 10.1128/genomeA.00514-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Escherichia coli strains belonging to sequence type (ST) 131 have disseminated worldwide as a cause of severe urinary tract infections and bacteremia (1). E. coli is a predominant pathogen causing neonatal sepsis and meningitis, and bacteremia-associated ST131 strains have only recently been reported in newborns (2–4). ST131 strains are commonly multidrug resistant (MDR) and show a high prevalence of extended-spectrum beta-lactamase (ESBL) resistance in some geographic regions (5). SCB34 is the first sequenced ST131 neonatal early-onset sepsis isolate. It was recovered from a 6-day-old premature newborn born at 22 weeks gestation. The mother had peripartum fever and acute chorioamnionitis for which she received ampicillin and gentamicin. Subsequent placenta culture did not yield pathogens. The newborn received ampicillin and amikacin immediately after birth but decompensated on day 6, when a blood culture grew E. coli. The local Institutional Review Board approved the collection of the clinical isolate and pertinent clinical data. Antimicrobial susceptibility testing, performed in accordance with CLSI guidelines (6), revealed that while SCB34 is not an ESBL-producing strain, it is resistant to ampicillin, gentamicin, tobramycin, and ciprofloxacin. While human ST131 isolates have shown variable adherence to and invasion of epithelial cells (4, 7), SCB34 has been shown to be highly invasive compared to other ST131 clinical isolates from bacteremic newborns (4). Whole-genome sequencing was performed on an Illumina MiSeq using a 250-bp paired-end library, which generated 5,910,264 reads with an average read length of 208 bp. The paired-end reads were assembled de novo using the A5 assembly pipeline (8). This yielded a database with 80 contigs, for a total contig length of 5,227,742 bp, with a 50.6% G+C content and an N50 of 205 kb. These data were submitted to the RAST server for annotation (9). Analysis of the adk, fumC, gyrB, icd, mdh, purA, and recA alleles confirmed that SCB34 is an ST131 strain (10). Although SCB34 is MDR, we did not find any evidence for plasmids in this strain, but we identified chromosomal antibiotic resistance determinants consistent with the antibiogram of this organism. Additional putative virulence factors common to pathogenic ST131 isolates (11) were identified in the genome, including the pathogen-associated iron transport iuc and fyu loci, at least three fimbrial gene clusters, several adhesins, and an RTX toxin. Other loci of note included curlin and cellulose biosynthesis loci (12, 13), both of which are important for biofilm formation. These data will be essential to our understanding of the properties of SCB34 contributing to the ability of this organism to cause neonatal bacteremia.

Nucleotide sequence accession numbers.

This whole-genome draft shotgun sequence has been deposited at GenBank under accession number JMKH00000000. The version described in this report is version JMKH01000000.
  12 in total

1.  Molecular epidemiology, plasmid analysis, virulence, and resistance of Escherichia coli isolated from neonatal intensive care units in Poland.

Authors:  Agnieszka Chmielarczyk; Monika Pobiega; Jadwiga Wójkowska-Mach; Dorota Romaniszyn; Paweł Adamski; Piotr B Heczko; Małgorzata Bulanda
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-24       Impact factor: 2.803

2.  Genotypic and phenotypic characterization of invasive neonatal Escherichia coli clinical isolates.

Authors:  Salika Mehreen Shakir; Jessica Marie Goldbeck; Denise Robison; Annette Marie Eckerd; Susana Chavez-Bueno
Journal:  Am J Perinatol       Date:  2014-02-24       Impact factor: 1.862

3.  Secretion and functional display of fusion proteins through the curli biogenesis pathway.

Authors:  Nani Van Gerven; Parveen Goyal; Guy Vandenbussche; Maia De Kerpel; Wim Jonckheere; Henri De Greve; Han Remaut
Journal:  Mol Microbiol       Date:  2014-02-12       Impact factor: 3.501

4.  Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals.

Authors:  Christa Ewers; Mirjam Grobbel; Ivonne Stamm; Peter A Kopp; Ines Diehl; Torsten Semmler; Angelika Fruth; Janine Beutlich; Beatriz Guerra; Lothar H Wieler; Sebastian Guenther
Journal:  J Antimicrob Chemother       Date:  2010-01-29       Impact factor: 5.790

6.  Escherichia coli isolates causing bacteremia via gut translocation and urinary tract infection in young infants exhibit different virulence genotypes.

Authors:  Farah Mahjoub-Messai; Philippe Bidet; Valérie Caro; Laure Diancourt; Valérie Biran; Yannick Aujard; Edouard Bingen; Stéphane Bonacorsi
Journal:  J Infect Dis       Date:  2011-05-05       Impact factor: 5.226

7.  Cellulose as an architectural element in spatially structured Escherichia coli biofilms.

Authors:  Diego O Serra; Anja M Richter; Regine Hengge
Journal:  J Bacteriol       Date:  2013-10-04       Impact factor: 3.490

8.  Virulence potential and adherence properties of Escherichia coli that produce CTX-M and NDM β-lactamases.

Authors:  Gisele Peirano; George L Mulvey; Glen D Armstrong; Johann D D Pitout
Journal:  J Med Microbiol       Date:  2013-01-14       Impact factor: 2.472

9.  Sex and virulence in Escherichia coli: an evolutionary perspective.

Authors:  Thierry Wirth; Daniel Falush; Ruiting Lan; Frances Colles; Patience Mensa; Lothar H Wieler; Helge Karch; Peter R Reeves; Martin C J Maiden; Howard Ochman; Mark Achtman
Journal:  Mol Microbiol       Date:  2006-06       Impact factor: 3.501

10.  The RAST Server: rapid annotations using subsystems technology.

Authors:  Ramy K Aziz; Daniela Bartels; Aaron A Best; Matthew DeJongh; Terrence Disz; Robert A Edwards; Kevin Formsma; Svetlana Gerdes; Elizabeth M Glass; Michael Kubal; Folker Meyer; Gary J Olsen; Robert Olson; Andrei L Osterman; Ross A Overbeek; Leslie K McNeil; Daniel Paarmann; Tobias Paczian; Bruce Parrello; Gordon D Pusch; Claudia Reich; Rick Stevens; Olga Vassieva; Veronika Vonstein; Andreas Wilke; Olga Zagnitko
Journal:  BMC Genomics       Date:  2008-02-08       Impact factor: 3.969

View more
  3 in total

1.  Route of infection alters virulence of neonatal septicemia Escherichia coli clinical isolates.

Authors:  Bryan K Cole; Edgar Scott; Marko Ilikj; David Bard; Darrin R Akins; David W Dyer; Susana Chavez-Bueno
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.752

2.  The Protective Influence of Chondroitin Sulfate, a Component of Human Milk, on Intestinal Bacterial Invasion and Translocation.

Authors:  Kathryn Y Burge; Lindsey Hannah; Jeffrey V Eckert; Aarthi Gunasekaran; Hala Chaaban
Journal:  J Hum Lact       Date:  2019-05-03       Impact factor: 2.219

Review 3.  The Role of Glycosaminoglycans in Protection from Neonatal Necrotizing Enterocolitis: A Narrative Review.

Authors:  Kathryn Burge; Erynn Bergner; Aarthi Gunasekaran; Jeffrey Eckert; Hala Chaaban
Journal:  Nutrients       Date:  2020-02-20       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.